Company profile
Baxiva company profile
Baxiva is an emerging biotechnology startup focused on the development of next-generation glycoconjugate vaccines designed to prevent and combat bacterial infections. By leveraging advanced glycoengineering technologies and innovative vaccine platforms, Baxiva aims to create more effective and longer-lasting immunizations that address both existing and emerging bacterial threats.
Business identity
- Website
- https://www.baxiva.com/
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 1-10 employees
- Founded
- 2025-01-01, Year
Headquarters
- Headquarters
- Schlieren, Zurich, Switzerland
- Postal code
- 8952
- Country code
- CH
- Continent
- Europe